Significance of initial ST segment changes for thrombolytic treatment in first inferior myocardial infarction

K Schröder, K Wegscheider, K-L Neuhaus, U Tebbe, R Schröder

Abstract

Objective—To evaluate the benefit to risk ratio of thrombolytic treatment in patients with small inferior acute myocardial infarction (AMI). Controlled studies relating the benefit from thrombolysis with initial electrocardiographic features are scarce and of limited sample size.

Design—Retrospective study of 728 patients with a first inferior AMI of six hours’ duration from the Intravenous Streptokinase in Acute Myocardial Infarction (ISAM) study comparing streptokinase with placebo stratified by the initial sum ST segment elevation (ΣST) of 0.8 mV or less and greater than 0.8 mV, and 636 patients from the International Joint Efficacy Comparison of Thrombolitics (INJECT) trial comparing double blind streptokinase with reteplase stratified by either ΣST or the presence of precordial ST segment depression.

Results—ISAM study patients with an ΣST of greater than 0.8 mV had a significant mortality benefit from streptokinase throughout six years, while those with an ΣST of 0.8 mV or less showed a trend to higher mortality at six months (6.3% streptokinase vs. 5.1% placebo). Despite significantly smaller infarcts and fewer clinical complications in patients with an ΣST of 0.8 mV or less (ISAM and INJECT) or the absence of precordial ST segment depression (INJECT) thrombolytic treatment was associated with higher early mortality than in those with initially larger ST segment deviations.

Conclusion—Thrombolytic treatment in patients with inferior AMI presenting with larger ST segment deviations is associated with improved survival throughout six years. The risk to benefit ratio, however, in terms of early mortality in patients who have an ΣST of 0.8 mV or less and no precordial ST segment depression may be unfavourable.

Heart 1997;77:506–511

Keywords: inferior myocardial infarction; ST segment deviation; thrombolytic treatment; mortality

Thrombolysis is claimed to be the treatment of choice for patients with acute myocardial infarction (AMI) of less than 12 hours duration presenting with ST segment elevation on their admission electrocardiogram (ECG), irrespective of the site of infarction. Mortality benefit in patients with inferior AMI is less, however, than in those with anterior AMI, and there is conflicting evidence regarding the efficacy of reperfusion treatment in patients with small inferior AMI. Inclusion of these low risk patients in thrombolytic trials may be a major reason why the benefit of thrombolytic treatment in patients with inferior AMI has been less dramatic than in those with anterior AMI.

Placebo controlled studies to clarify the precise indication for thrombolytic treatment in patients with inferior AMI are now unethical, and former controlled studies are scarce and limited by the small sample sizes. In the present study data from the Intravenous Streptokinase in Acute Myocardial Infarction (ISAM) study dataset, which provides a large well characterised cohort of patients, in whom initial ST segment elevation was measured, were reanalysed. Precordial ST segment depression was not measured in the ISAM study. Therefore, to bring the placebo controlled results on the initial sum ST segment elevation (ΣST) into relation with precordial ST segment depression, patients randomised in the recent International Joint Efficacy Comparison of Thrombolitics (INJECT) trial, were also reanalysed with stratification to both initial ΣST and presence of precordial ST segment depression.

Methods

PATIENTS

The series comprised 728 patients from the ISAM study and 636 from the INJECT trial. ECG substudy with a first inferior AMI. Patients older than 75 years in the ISAM study were excluded, while the INJECT trial was without an age limit. Each study was multicentre and double blind; the ISAM study compared streptokinase 1.5 MU with placebo, and the INJECT trial compared reteplase, 10 + 10 MU double bolus administration, with streptokinase. Patients presenting within six hours of the onset of symptoms in whom ST segment elevations of at least 0.1 mV in two limb leads or 0.2 mV in two contiguous chest leads were present were eligible.

ELECTROCARDIOGRAPHIC ANALYSIS

ST segment elevation was measured with lens intensified callipers to the nearest of 0.025 mV 20 ms after the end of QRS complex with PR
Significance of initial ST segment changes for thrombolytic treatment in first inferior myocardial infarction

ENZYME ANALYSIS

In the ISAM study, serum activity of creatine kinase (CK) isoenzyme, MB fraction, was measured at two hour intervals. The enzyme infarct size was calculated from the area under the curve. In the INJECT trial, peak serum activity of creatine kinase isoenzyme was measured in the participating hospitals and is expressed as a fraction of the upper normal limit of the different methods used.

QUANTITATIVE ANGIOGRAPHIC ANALYSIS

In the ISAM study, cardiac catheterisation and angiography were performed one month after infarction. The ejection fraction was calculated from an angiogram in a 30° right anterior oblique projection according to the area length method. Regional wall motion abnormalities were analysed in angiograms performed in the 30° right anterior oblique and 60° left anterior oblique projection, and calculated in square units as "regional dysynergic area" (DA). Briefly, the end diastolic and end systolic silhouettes were superimposed and divided into 48 segmental radii. The area between radii shortening by less than two standard deviations (SD) and the 2 SD range for systolic shortening in healthy individuals were considered as the DA.

STATISTICAL ANALYSIS

Two sample comparisons were performed using the two sided Mann-Whitney U test for continuous variables and Fisher's exact test for dichotomous variables. Survival curves were estimated according to Kaplan-Meier and compared using standardised log rank tests.

Two different methods were applied to estimate the dependence of six month mortality on increasing ΔST for different treatment groups. Cox regression analysis was used with the placebo or streptokinase treatment and ΔST elevation. This model assumes that the hazard of dying is proportional to the ΔST elevation in each treatment group, resulting in a global function of a type that is defined by the model. The significance of interaction terms—that is, the existence of different dependence functions in different treatment groups, can be tested within this model.

A moving average technique that is fairly common in time series analysis was used to detect deviations from the linear Cox model. First, discrete six month mortalities were calculated for intervals in steps of 0.1 mV. Second, weighted averaging functions were applied using a triangular weight function averaging over nine adjacent classes to achieve local smoothing of the crude mortality values. Ascending or descending trends in mortality were expressed by non-parametric rank biseral correlations τ, according to Glass, which can be tested with the Mann-Whitney U statistical test. The correlation coefficient and the corresponding P value can be interpreted in the same way as the Pearson correlation coefficient with P value for continuous variables.

Results

CUT-OFF POINT FOR LACK OF MORTALITY BENEFIT

Figure 1A (Cox regression analysis) and 1B (weighted averages) show six month mortality with the two applied estimation methods plotted by steps of increasing levels of ΔST on the baseline ECG for the ISAM patients (376 allocated to streptokinase and 352 to placebo) and INJECT trial patients with a first inferior AMI. In both models, patients in the ISAM study given placebo showed a continuous increase in mortality. In contrast, the curves for streptokinase treated patients were flat with some trend to lower mortality at higher ΔST. The interaction term of the Cox model was significant (2P = 0.025, fig 1A) as was the rank correlation τ = 0.23 (P = 0.029 one sided, fig 1B) for the ISAM study placebo group, while the rank correlation in the ISAM streptokinase group was not significant (τ = −0.02). In the INJECT trial, the mortality curves for patients randomised to thrombolytic treatment with either streptokinase or reteplase were also flat like those for the ISAM study streptokinase group (figs 1A and 1B).

Figure 1 Plots showing six month mortality with increasing ΔST segment elevation on the baseline electrocardiogram in 352 patients allocated to placebo and 376 given streptokinase (STK) in the ISAM study by (A) Cox regression analysis and (B) the moving averages technique. (B) The mortality curves cross between 0.8 and 0.9 mV (arrow). For comparison six month mortality for 636 patients of the INJECT trial who received thrombolytic treatment (reteplase [r-PA] or streptokinase) are displayed in each figure.
and a relatively normal ejection fraction. Benefit from thrombolytic treatment was small and statistically non-significant. Patients in the streptokinase and placebo groups with an \( \Sigma ST \) of more than 0.8 mV had significantly larger enzymatic infarct sizes and worse left ventricular function (table 1). Streptokinase was associated with a significant improvement in global and regional ejection fraction compared with that from placebo. Regional wall motion of the left ventricle was mostly impaired with placebo and greatly improved by streptokinase when evaluated by left anterior oblique ventriculograms. This angiographic angulation assessments in particular inferoseptal and posterolateral segments. The difference in enzymatic infarct size was statistically significant in the 141 patients randomised within three hours from the onset of symptoms (1:74 (1:0) IU/ml \( \times \) hours streptokinase \( v \) 2:33 (1:4) placebo, \( \text{P} = 0.01 \)).

**Mortality in Patients of the ISAM Study**

Mortality at six months in patients with an \( \Sigma ST \) of greater than 0.8 mV allocated to streptokinase was 4.6% (seven of 152 patients died) compared with 10.4% in those given placebo (12 of 115 patients, \( \text{P} = 0.07 \)). The actuarial curves for survival in figure 2A show a sustained mortality benefit throughout six years (\( \text{P} = 0.06 \)). The cut off point of 0.8 mV was derived from figure 1B. A shift to the right to 1.0 mV was associated with mortality differences in favour of streptokinase, which were conventionally significant.

In contrast, an initial \( \Sigma ST \) of 0.8 mV or less in patients allocated to streptokinase was associated with a trend to higher six month mortality (6.3 vs 5.1% placebo) and no long term mortality differences between patients given streptokinase or matching placebo (fig 2B).

**INJECT Trial: Baseline Characteristics and Clinical Event Rates According to Initial Segment Deviations**

Table 2 shows data according to \( \Sigma ST \) and the absence or presence of significant precardial ST segment depression. In each group, stratified by larger ST segment deviations, patients

### Table 1 Enzymatic infarct sizes and left ventricular function according to an initial \( \Sigma ST \) in patients with a first inferior AMI (ISAM study)

| \( \Sigma ST \) & Streptokinase | Placebo |
|---|---|---|
| Less than 0.8 mV | (n = 180) | (n = 174) |
| CK-MB AUC (IU/ml h) | 1.23 (0.9) | 1.37 (0.9) |
| Ejection fraction (%) | 61.2 (12) | 58.7 (12) |
| DA-RAO (units) | 14.8 (14) | 18.3 (15) |
| Data are means (SD). |

### Table 2 Age and clinical event rates* of 636 INJECT trial patients with a first inferior AMI according to \( \Sigma ST \) segment deviations on the baseline electrocardiogram

| \( \Sigma ST \) & Age (years) | P | Heart failure | Cardiogenic shock | AV block 2° or 3° | Atrial fibrillation | VENT | Reinfarction | PTCA/CABG |
|---|---|---|---|---|---|---|---|---|---|
| Less than 0.8 mV | (n = 336) | | | | | | | | |
| More than 0.8 mV | (n = 300) | | | | | | | | |
| \( \Sigma ST \) & Less than 0.2 | More than 0.2 |
| (n = 247) | (n = 389) | | | | | | | | |
| < 0.8 | 60.2 | 46.5 | 0.3 | 59.5 | 61.7 | 0.05 |
| Heart failure | 12.8 | 15.7 | 0.3 | 12.6 | 15.2 | 0.4 |
| Cardiogenic shock | 3.9 | 6.3 | 0.2 | 4.0 | 5.4 | 0.4 |
| AV block 2° or 3° | 9.8 | 13.3 | 0.2 | 7.7 | 13.9 | 0.02 |
| Atrial fibrillation | 6.0 | 9.7 | 0.08 | 7.3 | 8.0 | 0.4 |
| VENT | 9.5 | 18.0 | 0.002 | 8.1 | 17.0 | 0.001 |
| Reinfarction | 9.4 | 5.3 | 1.0 | 5.7 | 5.1 | 0.7 |
| PTCA/CABG | 22.0 | 25.8 | 0.3 | 21.1 | 25.4 | 0.2 |

*Present after enrolment. Data (except age) are percentages.

PTCA/CABG, percutaneous transluminal coronary angioplasty/coronary artery bypass graft surgery; \( \Sigma ST \), sum of precordial ST depression from leads V1-V4; VENT, ventricular fibrillation/sustained ventricular tachycardia; AV, atrioventricular; MI, myocardial infarction; \( \Sigma ST \), sum of ST segment elevation on the baseline electrocardiogram from leads II, III, aVF, V5 and V6.

### Enzymatic Infarct Size and Left Ventricular Function

Patients with an \( \Sigma ST \) of 0.8 mV or less in the ISAM study had relatively low enzyme release

![Figure 2](http://heart.bmj.com/article-figures/508.png)

**Figure 2** Kaplan-Meier survival curves for patients with a first inferior acute myocardial infarction; 376 allocated to streptokinase and 352 to placebo. The numbers of patients at risk at each time point are noted above the axes. (A) Patients with an \( \Sigma ST \) of greater than 0.8 mV on the baseline electrocardiogram; (B) those with an \( \Sigma ST \) of 0.8 mV or less.
Significance of initial ST segment changes for thrombolytic treatment in first inferior myocardial infarction

Table 3 Infarct sizes and six month mortality according to ST segment deviation on the baseline electrocardiogram (INJECT trial)

<table>
<thead>
<tr>
<th>ST segment deviation</th>
<th>Mortality (%)</th>
<th>P</th>
<th>ST segment elevation</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 0.8 mV</td>
<td>0.52 (0.2)</td>
<td>1.32 (0.5)</td>
<td>&lt; 0.0001</td>
<td>0.69 (0.4)</td>
</tr>
<tr>
<td>&gt; 0.8 mV</td>
<td>3.0 (0.3)</td>
<td>12.8 (8.6)</td>
<td>&lt; 0.0001</td>
<td>7.9 (6.3)</td>
</tr>
<tr>
<td>Mortality (%)</td>
<td>6.0 (20)</td>
<td></td>
<td></td>
<td>6.5 (16)</td>
</tr>
</tbody>
</table>

*Mean (SD).
†Values in parentheses are numbers of patients.

Table 4 Mortality and peak creatine kinase values according to different combinations of ST and precordial ST segment depression (INJECT trial)

<table>
<thead>
<tr>
<th>ST deviation</th>
<th>Mortality at 35 days</th>
<th>Peak creatine kinase</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 0.8 mV</td>
<td>4.5% (1/22)</td>
<td>8.2% (6/73)</td>
</tr>
<tr>
<td>&gt; 0.8 mV</td>
<td>4.9% (2/41)</td>
<td>10.2% (4/39)</td>
</tr>
</tbody>
</table>

Numbers in parentheses are numbers of patients except for peak CK (SD). ST segment elevation on the baseline electrocardiogram from leads II, III, aVF, V5 and V6.

Discussion

Despite more than a decade of extensive clinical trials the use of thrombolytic treatment in patients with inferior wall AMI continues to be controversial.1-11 Some investigators have recommended that thrombolysis should be limited to patients with anterior AMI.1-12 Others have claimed that thrombolytic treatment should be given to all patients presenting with ST segment elevation. Although the results are less convincing in patients with inferior AMI, treatment worldwide may save tens of thousands of lives each year.12-13 Only two controlled studies have attempted to relate the benefit from thrombolysis for first inferior AMI to the amount of myocardium at risk as assessed by the initial ST segment or the presence of significant precordial ST segment depression, respectively.1-2 Mortality risk could not be assessed accurately, however, because of the sample size and very low in-hospital mortality. The GISSI trial13 related hospital mortality to the number of leads with ST segment elevation on the admission ECG. Mortality benefit from streptokinase administration increased progressively with the number of affected ECG leads. Unfortunately, data are not provided for the subgroup of patients with inferior AMI.

Prediction of infarct size

The value of ST segment elevation on the admission ECG in patients with AMI as a prognostic indicator has been established over many years.14-16 The present ISAM study derived analysis showed significantly larger enzymatic infarct size and worse left ventricular function in patients with inferior AMI who had an ST segment of more than 0.8 mV compared with those with a ST segment of 0.8 mV and less receiving placebo or streptokinase (table 1).17

Currently, the presence or absence of precordial ST segment depression is preferred for prediction of infarct size in inferior AMI.17-18 PRECORDIAL ST segment depression reflects a larger area of ischaemia with extension to posterior or inferior regions, indicative of larger enzymatic infarct size and worse regional and global left ventricular function.17-21 Studies before the thrombolytic era showed that these patients had higher short and long term mortality.11-17 Bates et al19 also reported higher complication rates and worse left ventricular function after reperfusion treatment.
BENEFIT OF THROMBOLYTIC TREATMENT ON INFARCT SIZE

Streptokinase in patients with inferior AMI and an initial \( \Delta ST \) of greater than 0.8 mV significantly improved enzymatic infarct size and left ventricular function (table 1). This result corroborates previous studies in which significant benefit from thrombolysis in patients with either a larger \( \Delta ST \) or the presence of significant precordial \( ST \) segment depression was described. In keeping with the present analysis in patients with lesser amounts of \( ST \) segment deviation, left ventricular function in the control groups was relatively well preserved and improvement by thrombolytic treatment was small.

These data are valid for patient groups of sufficient sample size. In individual patients, however, the prognostic merit of the extent of initial \( ST \) segment depression is more limited. The overall correlations with enzymatic infarct size or final left ventricular function are fairly low. In fact, one of three patients with inferior AMI, who had initially smaller \( ST \) segment elevations, developed a larger infarct. Nevertheless, thrombolytic treatment in this generally low risk population would not be justified if an adverse effect on early mortality is suspected.

EVIDENCE OF INCREASED MORTALITY RISK WITH THROMBOLYTIC TREATMENT?

In the INJECT trial derived analysis mortality closely parallels that of the streptokinase treated patients in the ISAM study (figs 1A and 1B). Streptokinase clearly improved short and long term survival in patients who had an \( \Delta ST \) of more than 0.8 mV compared with those in those who received placebo in the ISAM study (figs 1 and 2). The magnitude of mortality benefit approaches that in patients with anterior AMI.

In patients with a smaller \( \Delta ST \), however, the death rates at six months tended to be higher in those allocated to streptokinase than in those allocated to placebo. In the INJECT trial all patients had thrombolytic treatment. Patients with lesser initial \( ST \) segment changes had significantly smaller infarcts and fewer clinical complications than those with an \( \Delta ST \) of greater than 0.8 mV or the presence of precordial \( ST \) segment depression (tables 2 and 3). In contrast, as in the streptokinase group of the ISAM study (fig 1), early mortality was higher in patients who had lesser \( ST \) segment deviations (tables 3 and 4). The virtually identical findings with thrombolytic treatment in both trials not only support the assumption of no benefit but even provide suggestive evidence for a slight increase in early mortality risk in patients with potentially small inferior AMI. As the sample size is far too small, an increased mortality risk cannot be substantiated by our data. It becomes apparent, however, if we assume that a small improvement in left ventricular performance within the near normal range (table 1) is not associated with any mortality benefit. Then the risks inherent to thrombolytic treatment will not be counterbalanced. Thrombolysis carries the risk of lethal bleeding complications and is associated with an early mortality hazard supposedly caused by reperfusion injury. The Fibrinolytic Therapy Trialists' Collaborative Group overview showed a non-significant overall mortality benefit from thrombolytic treatment of only 0-9% (absolute 7-5 v 8-4% control) for patients with inferior \( ST \) segment elevation, and there was an excess of deaths soon after thrombolysis (2-6% v 1-9% allocated control). As an excess of early deaths was not observed in patients with anterior \( ST \) segment elevation and the mortality benefit of streptokinase in patients presenting with larger inferior \( ST \) segment elevation was comparable to that known for anterior AMI patients (fig 1), the excess of early deaths of patients with inferior AMI are probably caused by patients presenting with small \( ST \) segment deviations, which are not outweighed by later mortality benefit.

LIMITATIONS

In the initial ISAM study analysis the amount of \( ST \) segment elevation on the admission ECG was not a prognostic indicator for an early mortality risk in patients with inferior AMI allocated streptokinase (in contrast to placebo). This might have reflected a game of chance. Confirmation by the INJECT trial ECG substudy, however, makes a play of chance unlikely. The present evaluation is clearly a retrospective subgroup analysis with its limitations. Such analyses are usually appropriate to generate a hypothesis for testing in a prospective randomised controlled trial. It is unlikely, however, that such an effort will be undertaken further because of the huge sample size required to prove a small mortality difference in patients, who generally have a relatively low risk of dying. Thus, the suspicion of a small increase in early mortality caused by thrombolytic treatment in patients with a small inferior AMI will probably not be
Significance of initial ST segment changes for thrombolytic treatment in first inferior myocardial infarction

511

Substantiated on the basis of a controlled trial.

How should the emerging concern about a possibly harmful effect of an accepted treatment in patients with AMI be managed? Such potentially important clinical data should not be ignored but rather presented to the medical community. Physicians may then decide how to consider these effects when making clinical decisions concerning patients with AMI.

Conclusions

Thrombolytic treatment is clearly indicated in patients with inferior AMI presenting within six hours from the onset of symptoms with either large infero(lateral) ST segment elevation or concomitant precordial ST segment depression. In addition, thrombolysis is beneficial in patients with an ST segment elevation of 0.1 mV or more in lead V4R, indicating right ventricular involvement. In contrast, the benefit from such treatment in patients with an initial EKG of 0.8 mV or less combined with a precordial ST segment depression of less than 0.2 mV is at least small. Thrombolysis may even carry an unfavourable benefit to risk ratio, particularly in patients at high risk for intracranial haemorrhage such as the elderly and those with hypertension or previous cerebrovascular events. Whether thrombolytic treatment should be considered only if small ST segment deviations are associated with advanced heart block or haemodynamic instability indicating larger infarcts. As with all treatments, patient selection has to be guided by weighing the potential benefit against the potential risks. In the INJECT trial EKG sub-study, 28% of patients with inferior AMI had small ST segment deviations (table 4). For inclusion into the INJECT trial ST segment elevation of 0.1 mV or greater in at least two limb leads was required. As it is common clinical practice to treat those with even lower ST segment elevations with thrombolytics, the proportion of patients in whom thrombolysis should be avoided is probably even larger. Whether such patients may benefit from direct coronary angioplasty is not known and remains speculative. The prognosis for patients with a first small inferior AMI is usually good and so any aggressive therapeutic approach may cause more harm than benefit.


